An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME)
Study Identifier
019-05-06-CR
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete
Results Available
Scientific Result Summary
Available Language(s): English
Study Details
Medical Condition
Study Drug
Phase
Phase 3
Sex
Female & Male
Age
21+ years
Protocol Summary
To demonstrate that niacin ER and simvastatin (NS) tablets, when compared to atorvastatin
(Lipitor®; Pfizer, Inc.), has superior high-density lipoprotein cholesterol (HDL-C) elevating
effects at Week 12 in subjects with type II hyperlipidemia or mixed dyslipidemia who are
currently off lipid-modifying therapy. This was a prospective, randomized, open-label,
blinded endpoint (PROBE) study.
Study Locations
Location
Status
Location
Anaheim, California, United States, 92801
Status
Not applicable
Location
Huntington Park, California, United States, 90255
Status
Not applicable
Location
Long Beach, California, United States, 90822
Status
Not applicable
Location
Sacramento, California, United States, 95825
Status
Not applicable
Location
Walnut Creek, California, United States, 94598
Status
Not applicable
Location
Brooksville, Florida, United States, 34613
Status
Not applicable
Showing {first} - {last} of {total} Results